患有良性前列腺增生症的患者的当前管理:来自当代意大利大型队列的多机构研究
Chiara Re1, Mattia Longoni2, Giuseppe Rosiello2
1Department of Urology and Division of Experimental Oncology, Urological Research Institute, IRCCS San Raffaele Scientific Institute, Milan, Italy - re.chiara@hsr.it.
Minerva urology and nephrology
|February 6, 2025
概括
被诊断为良性前列腺增生症 (BPH) 的男性经历下游泌尿道症状 (LUTS) 的恶化和生活质量的降低. 早期干预和坚持治疗对于控制BPH进展至关重要.
科学领域:
- 泌尿器科 泌尿器科 泌尿器科 泌尿器科
- 男人的健康 男人的健康
- 药理学 药理学是指药理学的学科.
背景情况:
- 在门诊环境中对良性前列腺增生症 (BPH) 的临床表现和管理的理解有限.
- 专注于药物和手术治疗,掩盖了门诊BPH患者的洞察力.
- 需要进行量身定制的分析,比较已知的BPH患者与新诊断的BPH患者.
研究的目的:
- 分析BPH患者在门诊环境中的临床表现和管理.
- 为了比较已知BPH患者与新诊断的BPH患者的特征和结果.
- 用国际前列腺症状评分 (IPSS) 和BPH影响指数 (BII) 来评估BPH对生活质量的影响.
主要方法:
- 由泌尿科医生给与BPH相关的下尿路症状 (LUTS) 的患者使用的前性问卷.
- 通过"密集前列腺益处"项目收集的数据分析.
- 患者人口统计学,症状严重程度 (IPSS),生活质量影响 (BII) 和先前诊断和新诊断的BPH组之间的治疗坚持情况的比较.
主要成果:
- 以前被诊断为BPH的患者年龄较大,病情更为共同,并报告了更高的IPSS中位数和严重症状.
- 对于健康的担忧和因尿路问题而失去的时间在先前BPH诊断的患者中显著增加.
- 尽管已经确立了治疗方法,但近90%的先前诊断的患者接受了BPH治疗调整后的泌尿外科检查,常见的处方包括补充剂/植物疗法药物,α阻断剂和5α-减少酶抑制剂.
结论:
- 患有先前BPH诊断的患者经历严重的,渐进的LUTS影响生活质量,即使在治疗中.
- 在初级保健中有效管理LUTS是必不可少的.
- 强调生活方式咨询,心血管风险控制和药物坚持对于改善BPH患者的结果至关重要.
相关概念视频
01:20Disorders of the Male Reproductive System
309
Men's health issues are increasingly recognized as significant, with several conditions posing common threats. Among these, testicular cancer is especially prevalent in younger men, particularly those aged 20 to 35 years. The disease often manifests as a painless mass in the testicles, sometimes accompanied by a sensation of heaviness or a dull ache.
Prostate disorders are another major concern. These conditions can impair urinary flow due to the prostate's location around the urethra....
Prostate disorders are another major concern. These conditions can impair urinary flow due to the prostate's location around the urethra....
309
01:23Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists
146
Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
146
01:28Treatment for Pulmonary Arterial Hypertension: Phosphodiesterase Inhibitors
127
Phosphodiesterase 5 (PDE5) inhibitors are potent enzymes that function to hydrolyze cyclic nucleotides to their corresponding 5' monophosphates. Their unique biochemical properties have been applied in treating Pulmonary Arterial Hypertension (PAH).
Among the PDE5 inhibitors, sildenafil (Revatio) stands out as a competitive and selective inhibitor. It operates by elevating cellular levels of cGMP and augmenting signaling through the cGMP-PKG pathway, promoting vasodilation. Upon oral...
Among the PDE5 inhibitors, sildenafil (Revatio) stands out as a competitive and selective inhibitor. It operates by elevating cellular levels of cGMP and augmenting signaling through the cGMP-PKG pathway, promoting vasodilation. Upon oral...
127